Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
COVID-19
•
General Rheumatology
•
Inflammatory arthritis
What is your approach to management of inflammatory arthritis in the setting of multisystem inflammatory syndrome in adults (MIS-A) after COVID?
Related Questions
Do oral NSAIDs and steroids have an effect on how you interpret synovial fluid leukocyte count?
What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
What is your approach to management of chronic neutropenia in a patient with Sjogren’s who was recently diagnosed with metastatic endometrial cancer and plans to start chemotherapy?
What is your approach to continuing or altering therapy when inheriting a patient with combined biologic immunosuppression that is in excess of guidelines?
In patients with rheumatologic disease on DMARDs and/or biologics how do you counsel them regarding blood donation?
Do you recommend Vitamin D and omega 3 fatty acid supplementation for prevention of autoimmune disease?
How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?
What is your approach to DVT prophylaxis in patients who require IVIG but are at increased risk for thrombotic events?
Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?
